Followers | 2732 |
Posts | 55279 |
Boards Moderated | 4 |
Alias Born | 08/10/2012 |
![](https://investorshub.advfn.com/uicon/355710.png?cb=1487630365)
Monday, July 25, 2022 9:54:15 AM
Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has entered a Heads of Terms (also known as a Letter of Intent (“LOI”)) agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin (“PGT”), a novel protein complex for targeted treatment of advanced cancers.
PGT is designed to deliver paclitaxel to cancer cells over-expressing Transferrin Receptor 1, also known as CD71 or TFR1. Paclitaxel is a commercially successful drug approved by the U.S. Food and Drug Administration (“FDA”) in two variations, solvent-based paclitaxel (sb-paclitaxel, brand name Taxol®) and protein-based paclitaxel (nab-paclitaxel, brand name ABRAXANE®). Sb-paclitaxel is approved for breast, ovarian, and lung cancer and Kaposi’s Sarcoma, while nab-paclitaxel is approved for breast, pancreatic, and non-small cell lung cancer. Each are often used off-label for a variety of hard-to-treat solid and liquid tumors.
Gallium nitrate (brand name GANITE®) is FDA-approved for hypercalcemia of malignancy, a common finding in patients with advanced stage cancer. With characteristics similar to iron, gallium has anti-cancer activity and has been shown to have synergistic activity in combination with other anti-cancer drugs.
Transferrin is a human blood protein that functions as an iron transport and natural ligand that binds to CD71-positive cells. Nab-paclitaxel uses albumin as its protein component. Pre-clinical research on PGT suggests that switching the protein component to transferrin could have potential advantages over albumin for developing a new targeted therapy, one that delivers a second, non-cross resistant agent, gallium.
“CD71 is regarded as an optimal target in oncology, yet it has proven elusive to new therapeutics because of its ubiquitous expression on the surface of generic cells, a challenge that we believe PGT could potentially overcome while hitting tumor cells with both paclitaxel and gallium,” commented Andrew Kucharchuk, Chief Executive Officer at Adhera Therapeutics. “Owing to the fact that CD71 is overly expressed on many different refractory tumors, we see an opportunity to develop a strategy that is focused on a specific cancer while simultaneously working to evolve a new drug for a tumor-agnostic secondary indication. PGT is a tremendous value add to our pipeline and we look forward to advancing the research on this promising new therapy.”
While best efforts are anticipated to advance the Heads of Terms agreement to an executed definitive agreement pursuant to which Adhera will acquire PGT, no assurances of such a development are expressed, implied, or guaranteed.
https://finance.yahoo.com/news/adhera-therapeutics-signs-letter-intent-131500161.html
Recent ATRX News
- Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 01/30/2024 09:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:25:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:01:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:51:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:35:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 08:58:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 07:32:22 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 08:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 08:54:24 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM